Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette; Olivier Hermine; Pierre-Louis Tharaux; Matthieu Resche-Rigon; Philippe Gabriel Steg; Raphaël Porcher; Philippe Ravaud

doi:10.1001/jamainternmed.2021.2209

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.

Authors

Xavier Mariette^{1

2}, Olivier Hermine^{3

4}, Pierre-Louis Tharaux⁵, Matthieu Resche-Rigon^{6

7}, Philippe Gabriel Steg^{8

9}, Raphaël Porcher¹⁰, Philippe Ravaud^{10

11}

Affiliations

¹ Department of Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
² Université Paris-Saclay, Institut national de la santé et de la recherche médicale (INSERM) UMR1184, Le Kremlin Bicêtre, Le Kremlin Bicêtre, France.
³ Department of Hematology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Institut Imagine, Université de Paris, INSERM UMR1183, Paris, France.
⁵ Paris Cardiovascular Center, Université de Paris, INSERM, F-75015 Paris, France.
⁶ Université de Paris, ECSTRRA Team, Centre of Research Epidemiology and Statistics, INSERM UMR1153, Paris, France.
⁷ URC Saint-Louis, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
⁸ Department of cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Université de Paris, INSERM U1148, Paris, France.
¹⁰ Université de Paris, Centre of Research Epidemiology and Statistics, INSERM U1153, Paris, France.
¹¹ Centre d'Epidémiologie Clinique, Assistance Publique des Hôpitaux de Paris, Hôpital Hôtel Dieu, Paris, France.

Abstract

This follow-up study of the CORIMUNO-TOCI-1 randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
COVID-19 Drug Treatment*
Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Intensive Care Units / statistics & numerical data
Randomized Controlled Trials as Topic
Severity of Illness Index*
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab